Electrospun pvp/pva nanofiber mat as a novel potential transdermal drug-delivery system for buprenorphine: A solution needed for pain management

Abstract

Over the past several decades, the formulation of novel nanofiber-based drug-delivery systems has been a frequent focus of scientists around the world. Aiming to introduce a novel nan-ofibrous transdermal drug-delivery system to treat pain, the nanofiber mats of buprenorphine-loaded poly (vinyl pyrrolidone) (Bup/PVP) and buprenorphine-loaded poly(vinyl alcohol)/poly(vi-nyl pyrrolidone) (Bup/PVP/PVA) were successfully fabricated by the electrospinning process for transdermal drug delivery. Similarly, PVP and PVP/PVA nanofibers were fabricated in the same conditions for comparison. The viscosity and electrical conductivity of all electrospinning solutions were measured, and nanofiber mats were characterized by scanning electron microscopy (SEM), atomic force microscopy (AFM), Fourier transform infrared (FT-IR) spectroscopy and contact angle analysis. The conductivity of PVP and PVP/PVA solutions showed a considerable increase by the addition of buprenorphine due to the polarity of buprenorphine. SEM images showed a smooth, fine and porous nanofibrous structure without any adhesion or knot for all of the samples. The contact angle analysis showed the increased hydrophilicity and wettability of PVP/PVA and Bup/PVP/PVA nanofibers compared to PVP and Bup/PVP nanofibers which can be attributed to the addition of PVA. Attenuated total reflectance (ATR) FT-IR results confirmed that the electrospin-ning process did not affect the chemical integrity of the drug. For the modification of the drug release rate, the cross-linking of nanofiber mats was carried out using glutaraldehyde. Drug release measurements using high-performance liquid chromatography (HPLC) analysis demonstrated that Bup/PVP/PVA nanofibers exhibited better physical and chemical properties compared to Bup/PVP. Furthermore, the cross-linking of nanofibers led to an increase in drug release time. Thus, the novel buprenorphine-loaded nanofibers can be efficient biomaterial patches for transdermal delivery against pain improving carrier retention and providing a controlled release of the drug. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.